

SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	00786/405003
	Serial No.	10/698,734
	Applicant	Denise Faustman
	Filing Date	October 31, 2003
	Group	1644
	IDS Filed	December 29, 2008

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
	5,919,452	July 6, 1999	Le et al.
	5,370,870	December 6, 1994	Wong et al.
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)			
	Aranda et al., "Analysis of Intestinal Lymphocytes In Mouse Colitis Mediated by Transfer of CD4 <sup>+</sup> , CD45RB <sup>high</sup> T Cells To SCID Recipients," <i>J. Immunol.</i> 158:3464-3473, 1997.		
	Caetano et al., "Effect of Methotrexate (MTX) On NAD(P) <sup>+</sup> Dehydrogenases of HeLa Cells: Malic Enzyme, 2-Oxoglutarate and Isocitrate Dehydrogenases," <i>Cell Biochem. Funct.</i> 15:259-264, 1997.		
	Dinarello, "Interleukin-1, Interleukin-1 Receptors and Interleukin-1 Receptor Antagonist," <i>Int'l. Rev. Immunol.</i> 16:457-499, 1998.		
	Fukada et al., "Two Signals are Necessary for Cell Proliferation Induced by a Cytokine Receptor gp130: Involvement of STAT3 in Anti-Apoptosis," <i>Immunity</i> 5:449-460, 1996.		
	Genestier et al., "Immunosuppressive Properties of Methotrexate: Apoptosis and Clonal Deletion of Activated Peripheral T Cells," <i>J. Clin. Invest.</i> 102:322-328, 1998.		
	Gerich et al., "Advances in Diabetes for the Millennium: Understanding Insulin Resistance," <i>MedGenMed.</i> 6:11, 2004.		
	Gottlieb et al., "Cell Acidification in Apoptosis: Granulocyte Colony-Stimulating Factor Delays Programmed Cell Death In Neutrophils by Up-Regulating the Vacuolar H(+)-ATPase," <i>Proc. Nat'l. Acad. Sci. USA</i> 92:5965-5968, 1995.		
	Grewal et al., "Local Expression of Transgene Encoded TNF $\alpha$ in Islets Prevents Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice By Preventing the Development of Auto-Reactive Islet-Specific T Cells," <i>J. Exp. Med.</i> 184:1963-1974, 1996.		
	The Merck Manual of Diagnosis and Therapy, Beers and Berkow, Eds., Published by Merck Research Laboratories, 17 <sup>th</sup> Ed., pages 165-171, 1999.		

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/~~

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.  Serial No.  Applicant  Filing Date  Group  IDS Filed	00786/405003  10/698,734  Denise Faustman  October 31, 2003  1644  December 29, 2008
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Raab and Grmeiner, "In Vitro Evaluation of Methotrexate and Azathioprine for Antipsoriatic Activity," <i>Arch. Derm. Res.</i> 253:77-84, 1975.
	Rajagopalan et al., "Pathogenic Anti-DNA Autoantibody-Inducing T Helper Cell Lines from Patients with Active Lupus Nephritis: Isolation Of CD4 <sup>+</sup> 8 <sup>+</sup> T Helper Cell Lines that Express the Gamma Delta T-Cell Antigen Receptor," <i>Proc. Nat'l. Acad. Sci. USA</i> 87:7020-7024, 1990.
	Schuppan, "Current Concepts of Celiac Disease Pathogenesis," <i>Gastroenterol.</i> 119:234-242, 2000.

EXAMINER	/Michail Belyavskiy/ (02/05/2009)
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.~~ /MB/